These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 16527007

  • 1. The use of zoledronic acid for Paget's disease of bone.
    Maricic M.
    Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
    [Abstract] [Full Text] [Related]

  • 2. Zoledronic acid for Paget's disease of bone.
    Maricic M.
    Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
    [Abstract] [Full Text] [Related]

  • 3. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM, Scott LJ.
    Drugs; 2007 Dec; 67(5):793-804. PubMed ID: 17385948
    [Abstract] [Full Text] [Related]

  • 4. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 5. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
    Gennari L, Merlotti D, Mossetti G, Rendina D, De Paola V, Martini G, Nuti R.
    Mini Rev Med Chem; 2009 Aug; 9(9):1052-63. PubMed ID: 19689402
    [Abstract] [Full Text] [Related]

  • 6. Zoledronic acid for treatment of Paget's disease of bone.
    Devogelaer JP, Manicourt DH.
    Expert Opin Pharmacother; 2007 Nov; 8(16):2863-9. PubMed ID: 17956205
    [Abstract] [Full Text] [Related]

  • 7. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
    Conesa Mateos A, Rotés Sala D, Almirall Bernabé M, Carbonell Abelló J.
    Med Clin (Barc); 2006 Oct 28; 127(16):635-6. PubMed ID: 17145033
    [No Abstract] [Full Text] [Related]

  • 8. Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone.
    Polyzos SA.
    Clin Rheumatol; 2011 Jan 28; 30(1):149-50. PubMed ID: 21053036
    [No Abstract] [Full Text] [Related]

  • 9. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
    Polyzos SA, Anastasilakis AD, Anagnostis P, Kita M, Arsos G, Moralidis E, Papatheodorou A, Terpos E.
    Endokrynol Pol; 2012 Jan 28; 63(4):312-5. PubMed ID: 22933168
    [Abstract] [Full Text] [Related]

  • 10. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F.
    Clin Exp Rheumatol; 2007 Jan 28; 25(3):464-6. PubMed ID: 17631747
    [Abstract] [Full Text] [Related]

  • 11. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.
    Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM, Reginster JY, Rozenberg S, Boonen S, Belgian Bone Club.
    Osteoporos Int; 2008 Aug 28; 19(8):1109-17. PubMed ID: 18504638
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of Paget's disease of bone with zoledronic acid].
    Body JJ, Sternon J.
    Rev Med Brux; 2005 Aug 28; 26(6):513-7. PubMed ID: 16454155
    [Abstract] [Full Text] [Related]

  • 13. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan 28; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D.
    Bone; 2006 Feb 28; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [Abstract] [Full Text] [Related]

  • 15. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM.
    Nat Clin Pract Rheumatol; 2006 Apr 28; 2(4):186-7. PubMed ID: 16932682
    [No Abstract] [Full Text] [Related]

  • 16. [Treatment of Paget's disease of bone: importance of the zoledronic acid].
    Griz L, Colares V, Bandeira F.
    Arq Bras Endocrinol Metabol; 2006 Oct 28; 50(5):845-51. PubMed ID: 17160207
    [Abstract] [Full Text] [Related]

  • 17. [Therapy of Paget's disease].
    Kurth AA.
    Orthopade; 2007 Feb 28; 36(2):118, 120-3. PubMed ID: 17252256
    [Abstract] [Full Text] [Related]

  • 18. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.
    N Engl J Med; 2005 Sep 01; 353(9):898-908. PubMed ID: 16135834
    [Abstract] [Full Text] [Related]

  • 19. [Intravenous bisphosphonates for bone Paget's disease: higher risk of adverse events].
    Grados D, Martínez-Morillo M, Holgado S, Erra A.
    Med Clin (Barc); 2014 May 20; 142(10):469-70. PubMed ID: 24120108
    [No Abstract] [Full Text] [Related]

  • 20. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M, Prokop LJ, Tebben P, Murad MH.
    Osteoporos Int; 2015 Jul 20; 26(7):1875-91. PubMed ID: 26037791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.